Four-year outcome in psychopharmacologically treated adults with attention-deficit/hyperactivity disorder: A questionnaire survey

Journal of Clinical Psychiatry

Volumn 74, Issue 1, 2013, Pages

  Lensing, Michael B ^a   Zeiner, Pal ^b   Sandvik, Leiv ^a   Opjordsmoen, Stein ^b,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Division of Mental Health and Addiction   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; DEXAMPHETAMINE; METHYLPHENIDATE;

ADULT; ADULT ADHD SELF REPORT SCALE; ATTENTION DEFICIT DISORDER; COMORBIDITY; DRUG APPROVAL; DRUG EFFICACY; DRUG MISUSE; DRUG SAFETY; DRUG WITHDRAWAL; DSM-IV; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOLOGY; QUESTIONNAIRE; REVIEW; SCREENER AND THE MENTAL HEALTH INDEX 5; SYMPTOM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84873840370     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12m07714     Document Type: Review

References (58)

1. Biederman J, Petty CR, Monuteaux MC, et al. Adult psychiatric outcomes of girls with attention deficit hyperactivity disorder: 11-year follow-up in a longitudinal case-control study. Am J Psychiatry. 2010;167(4):409-417.
2. Biederman J, Petty CR, Clarke A, et al. Predictors of persistent ADHD: an 11-year follow-up study. J Psychiatr Res. 2011;45(2):150-155.
3. Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942-948.
4. Remschmidt H; Global ADHD Working Group. Global consensus on ADHD/HKD. Eur Child Adolesc Psychiatry. 2005;14(3):127-137.
5. Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007;190(5):402-409.
6. Able SL, Johnston JA, Adler LA, et al. Functional and psychosocial impairment in adults with undiagnosed ADHD. Psychol Med. 2007;37(1): 97-107.
7. Barkley RA, Fischer M, Smallish L, et al. Young adult follow-up of hyperactive children: antisocial activities and drug use. J Child Psychol Psychiatry. 2004;45(2):195-211.
8. Mannuzza S, Klein RG. Long-term prognosis in attention-deficit/ hyperactivity disorder. Child Adolesc Psychiatr Clin N Am. 2000;9(3): 711-726.
9. Kendall T, Taylor E, Perez A, et al Guideline Development Group. Diagnosis and management of attention-deficit/hyperactivity disorder in children, young people, and adults: summary of NICE guidance. BMJ. 2008;337(1):a1239.
10. Santosh PJ, Sattar S, Canagaratnam M. Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults. CNS Drugs. 2011;25(9):737-763.
11. Godfrey J. Safety of therapeutic methylphenidate in adults: a systematic review of the evidence. J Psychopharmacol. 2009;23(2):194-205.
12. Torgersen T, Gjervan B, Rasmussen K. Treatment of adult ADHD: is current knowledge useful to clinicians? Neuropsychiatr Dis Treat. 2008; 4(1):177-186.
13. Bejerot S, Ryden EM, Arlinde CM. Two-year outcome of treatment with central stimulant medication in adult attention-deficit/hyperactivity disorder: a prospective study. J Clin Psychiatry. 2010;71(12):1590-1597.
14. Wender PH, Reimherr FW, Marchant BK, et al. A one year trial of methylphenidate in the treatment of ADHD. J Atten Disord. 2011; 15(1):36-45.
15. Surman CB, Monuteaux MC, Petty CR, et al. Representativeness of participants in a clinical trial for attention-deficit/hyperactivity disorder? comparison with adults from a large observational study. J Clin Psychiatry. 2010;71(12):1612-1616.
16. Weiss MD, Gibbins C, Goodman DW, et al. Moderators and mediators of symptoms and quality of life outcomes in an open-label study of adults treated for attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2010;71(4):381-390.
17. Olfson M, Marcus SC, Zhang HF, et al. Continuity in methylphenidate treatment of adults with attention-deficit/hyperactivity disorder. J Manag Care Pharm. 2007;13(7):570-577.
18. Perwien A, Hall J, Swensen A, et al. Stimulant treatment patterns and compliance in children and adults with newly treated attention-deficit/ hyperactivity disorder. J Manag Care Pharm. 2004;10(2):122-129.
19. Adler LA, Spencer TJ, Williams DW, et al. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Atten Disord. 2008;12(3):248-253.
20. Adler LA, Orman C, Starr HL, et al. Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year study. J Clin Psychopharmacol. 2011;31(1):108-114.
21. Biederman J, Spencer TJ, Wilens TE, et al; SLI381.304 study group. Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. 2005; 10(suppl 20):16-25.
22. Aanonsen NO, Prietz R, Sandven I, et al. Rapport til Sosial- og Helsedirektoratet. Utprovende behandling med sentralstimulerende legemidler til voksne med hyperkinetisk forstyrrelse/ADHD. Erfaringer fra proveperioden oktober 1997 til august 2003. (Report to the Norwegian Directorate of Health. Testing treatment with stimulant medication in adults with hyperkinetic disorder/ADHD. Experiences from the test-period from October 1997 to August 2003). Oslo, Norway: Ullevaal University Hospital; 2004.
23. Aanonsen NO, Prietz R, Gorvell PF, et al. Utprovende behandling med sentralstimulerende legemidler til voksne med hyperkinetisk forstyrrelse/ ADHD. Supplement til "Rapport til Sosial- og helsedirektoratet. Erfaringer fra proveperioden oktober 1997 til august 2003. (Testing treatment with stimulant medication in adults with hyperkinetic disorders/ADHD. Supplement to "Report to the Norwegian Directorate of Health. Experiences from the test-period from October 1997 to August 2003). Oslo, Norway: Ullevaal University Hospital; 2005.
24. World Health Organization (WHO). The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva, Switzerland: World Health Organization; 1992.
25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington DC: American Psychiatric Association; 1994.
26. Vassend O, Lian L, Andersen HT. Norske versjoner av NEO personality inventory, symptom checklist 90 revised og Giessen symptom checklist. Del 1 (Norwegian versions of NEO personality inventory, symptom checklist 90 revised and Giessen symptom checklist, pt 1). Tidsskr Nor Psykol foren. 1992;29:1150-1160.
27. Amen D. General Adult ADD Symptom Checklist. In: Clark C, ed. ADHD Throughout The Life Span. Las Vegas, NV: Randon Clark Publications; 1997:28-33.
28. World Health Organization (WHO) and Workgroup on Adult ADHD. Adult ADHD Self-Report Scale (ASRS) Symptom Checklist; 2003 http://misc.medscape.com/pi/ editorial/clinupdates/2003/2499/ adler-adhdscreen.pdf. Accessed August 29, 2012.
29. Kessler RC, Adler LA, Gruber MJ, et al. Validity of the World Health Organization Adult ADHD Self-Report Scale (ASRS) Screener in a representative sample of health plan members. Int J Methods Psychiatr Res. 2007;16(2):52-65.
30. Taylor A, Deb S, Unwin G. Scales for the identification of adults with attention deficit hyperactivity disorder (ADHD): a systematic review. Res Dev Disabil. 2011;32(3):924-938.
31. Ware JE Jr, Kosinski M, Gandek B. SF-36 Health Survey: Manual & Interpretation Guide. 2nd ed. Lincoln, RI: Quality Metric Incorporated; 2000.
32. Loge JH, Kaasa S. Short form 36 (SF-36) health survey: normative data from the general Norwegian population. Scand J Soc Med. 1998;26(4): 250-258.
33. Cuijpers P, Smits N, Donker T, et al. Screening for mood and anxiety disorders with the five-item, the three-item, and the two-item Mental Health Inventory. Psychiatry Res. 2009;168(3):250-255.
34. Strand BH, Dalgard OS, Tambs K, et al. Measuring the mental health status of the Norwegian population: a comparison of the instruments SCL-25, SCL-10, SCL-5 and MHI-5 (SF-36). Nord J Psychiatry. 2003; 57(2):113-118.
35. Kelly MJ, Dunstan FD, Lloyd K, et al. Evaluating cutpoints for the MHI-5 and MCS using the GHQ-12: a comparison of five different methods. BMC Psychiatry. 2008;8(1):10.
36. Halmoy A, Fasmer OB, Gillberg C, et al. Occupational outcome in adult ADHD: impact of symptom profile, comorbid psychiatric problems, and treatment: a cross-sectional study of 414 clinically diagnosed adult ADHD patients. J Atten Disord. 2009;13(2):175-187.
37. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-723.
38. Torgersen T, Gjervan B, Rasmussen K. ADHD in adults: a study of clinical characteristics, impairment and comorbidity. Nord J Psychiatry. 2006;60(1):38-43.
39. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005; 353(5):487-497.
40. Adler LD, Nierenberg AA. Review of medication adherence in children and adults with ADHD. Postgrad Med. 2010;122(1):184-191.
41. McCarthy S, Asherson P, Coghill D, et al. Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults. Br J Psychiatry. 2009;194(3):273-277.
42. Charach A, Ickowicz A, Schachar R. Stimulant treatment over five years: adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatry. 2004;43(5):559-567.
43. Winterstein AG, Gerhard T, Shuster J, et al. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database. Ann Pharmacother. 2008;42(1):24-31.
44. Jonsdottir H, Opjordsmoen S, Birkenaes AB, et al. Medication adherence in outpatients with severe mental disorders: relation between self-reports and serum level. J Clin Psychopharmacol. 2010;30(2):169-175.
45. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry. 2010;71(6):754-763.
46. Wilens TE, Morrison NR, Prince J. An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults. Expert Rev Neurother. 2011;11(10):1443-1465.
47. Wilens T, McBurnett K, Stein M, et al. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry. 2005;44(10):1015-1023.
48. Volkow ND, Wang GJ, Tomasi D, et al. Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder. J Neurosci. 2012;32(3):841-849.
49. Powell SG, Thomsen PH, Frydenberg M, et al. Long-term treatment of ADHD with stimulants: a large observational study of real-life patients. J Atten Disord. 2010;15(6):439-451.
50. Ramos-Quiroga JA, Casas M. Achieving remission as a routine goal of pharmacotherapy in attention-deficit hyperactivity disorder. CNS Drugs. 2011;25(1):17-36.
51. Steele M, Jensen PS, Quinn DM. Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther. 2006; 28(11):1892-1908.
52. van de Loo-Neus GH, Rommelse N, Buitelaar JK. To stop or not to stop? how long should medication treatment of attention-deficit hyperactivity disorder be extended? Eur Neuropsychopharmacol. 2011;21(8):584-599.
53. Biederman J, Petty CR, Evans M, et al. How persistent is ADHD? a controlled 10-year follow-up study of boys with ADHD. Psychiatry Res. 2010;177(3):299-304.
54. Biederman J, Petty CR, O'Connor KB, et al. Predictors of persistence in girls with attention deficit hyperactivity disorder: results from an 11-year controlled follow-up study. Acta Psychiatr Scand. 2012;125(2):147-156.
55. Biederman J, Faraone SV, Monuteaux MC, et al. Gender effects on attention-deficit/hyperactivity disorder in adults, revisited. Biol Psychiatry. 2004;55(7):692-700.
56. Rasmussen K, Levander S. Untreated ADHD in adults: are there sex differences in symptoms, comorbidity, and impairment? J Atten Disord. 2009;12(4):353-360.
57. Murphy P, Schachar R. Use of self-ratings in the assessment of symptoms of attention deficit hyperactivity disorder in adults. Am J Psychiatry. 2000;157(7):1156-1159.
58. Manor I, Vurembrandt N, Rozen S, et al. Low self-awareness of ADHD in adults using a self-report screening questionnaire. Eur Psychiatry. 2012;27(5):314-320.